Supported by the National Key High-technology R&D Programm for the 11th Five-year Plan (Grant No. 2008ZX10001-006);the Ministry of Health Clinical HIV/AIDS Research Grant (Grant No. 2007-2009);the Therapeutic Drug Monitoring of Anti-HIV Regimens and HIV Resistance Testing in Beijing HIV/AIDS Patients Receiving HAART,Beijing Science and Technology Program Fund (Grant No. D0906003040491)
HXB2 is primarily used as a template strain in developing HIV vaccines in Europe and the US. However,it is not yet known whether the strain can induce strong HIV-specific CD8+ T cell responses in Chinese HIV/AIDS pati...
In order to understand the variation of humoral and cellular immune responses to A16R live spore and AVA vaccine and to identify efficient immunological parameters for the early evaluation of post immu- nization in mi...